MangoRx falls as Lilly sues firm over sale of copycat weight-loss drug

Mangoceuticals

21/10/2024 10:30

** Shares of telehealth company Mangoceuticals  MGRX.O ,
also known as MangoRx, fall 4% to $2.43 before the bell 
    ** Eli Lilly  LLY.N  sues three medical spas and online
vendors, including MangoRx, for selling products claiming to
contain tirzepatide, the main ingredient in its popular
weight-loss drug Zepbound
    ** Earlier this month, MangoRx launched its own brand called
"Trim" - a compounded, oral dissolvable tirzepatide tablet 
    ** Lilly said MangoRx was selling an oral version despite
the lack of any study showing that formulation to be safe and
effective 
    ** MangoRx also sells "Slim", its oral compounded
formulation of semaglutide, the active ingredient in Novo
Nordisk's  NOVOb.CO  Wegovy 
    ** MangoRx did not immediately respond to a request for
comment 
    ** As of last close, MGRX down nearly 42% YTD 

 (Reporting by Bhanvi Satija in Bengaluru)
 ((Bhanvi.Satija@thomsonreuters.com; Outside U.S. +91
9873062788;))